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Introduction 
Piroxicam,  4–hydroxy–2–methyl–N–2–pyridinyl–2H–
1,2–benzothiazine–3–carboxamide 1,1–dioxide (PX), is 
non–steroidal  anti–inflammatory,  and  analgesic  agent 
belonging to a new class of compounds called oxicams. 
It  is  widely  used  in  the  treatment  of  patients  with 
rheumatologic disorders.
1 
PX  is  readily  absorbed  after  oral  or  rectal 
administration. After a single oral dose of 20 mg of PX, 
its  peak  plasma  concentration  and  plasma  half–life 
were  4.5  μg/mL  and  35–60  h,  respectively.  PX  is 
extensively  metabolized  to  5–hydroxypiroxicam  (5–
HP)  and  the  hydroxylated  metabolite  undergoes 
subsequent  glucuronidation.  About  2–5%  of  an  oral 
dose is excreted unchanged in urine, and under steady 
state conditions, 75% of a dose is excreted as either 5–
HP or 5–HP glucuronide in urine and feces.
2 
The employment of several analytical methods such as 
membrane  sensors,
1  potentiometric  titration,
3 
spectrophotometry,
3–7  spectrofluorimetry,
8–11 
luminescence
12  and  chromatography
5  has  been 
proposed for the determination of PX in pharmaceutical 
preparations.  On  the  other  hand,  different  analytical 
methods  such  as  derivative  spectrophotometry,
2 
spectrofluorimetry
10,13  and  high  performance  liquid 
chromatography  (HPLC)
14–20  have  been  reported  for 
the determination of PX in different biological fluids.  
In general, HPLC has been the most employed method 
to measure PX in different biological fluids. Most of 
these  methods  require  liquid–liquid  extraction  (LLE) 
with  consecutive  evaporation.
15–19  The  extraction 
procedure is prone to complications because it involves 
several separate steps, which not only make the method 
tedious  and  time  consuming  but  also  increase  the 
potential of introducing a bias in the results.
20 
Simple,  effective  and  environmentally–friendly 
extraction procedures are still in demand. Nowadays, a 
new  mode  of  liquid–phase  micro–extraction  (LPME) 
named DLLME as a high–performance, powerful, rapid 
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Purpose: Piroxicam, is non–steroidal anti–inflammatory and analgesic agent, which is 
widely used in the treatment of patients with rheumatologic disorders. A new analytical 
approach  based  on  the  dispersive  liquid–liquid  microextraction  (DLLME)  has  been 
developed for the extraction and determination of PX in pharmaceutical preparation and 
human urine. Methods: From the PX standard solution or solutions prepared from real 
samples, aliquot volumes were pipetted into centrifuge tubes and mixed with acetate 
buffer at pH 3.0 and NaCl solution. The contents were subjected to the DLLME, so 700 
µL of  methanol  containing  70  µL  of chloroform  was  injected  rapidly  into  a  sample 
solution. A cloudy solution was rapidly produced and the PX extracted into dispersed 
fine droplets. The mixture was centrifuged, thus these fine droplets of chloroform were 
settled. The supernatant aqueous phase was readily decanted, then the remained organic 
phase was diluted with ethanol and the absorbance measured at 355 ± 3 nm against a 
reagent blank. Results: The main factors affecting the extraction efficiency such as pH, 
extraction  and  disperser  solvent  types  and  etc.  were  studied  and  optimized 
systematically. Under optimized conditions, the calibration graphs were linear over the 
range of 0.2 to 4.8 μg/mL. The limit of detection and relative standard deviation were 
found to be 0.058 μg/mL and 2.83%, respectively. Relative recoveries in the spiked 
samples ranged from 97 to 110%. Conclusion: Using the developed method PX can be 
analyzed in pharmaceutical formulation and human urine sample in a simpler, cheaper 
and more rapid manner.  
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and inexpensive ME method has been proposed.
21 The 
basic  principles  of  this  method  is  dispersion  of 
extraction solvent (immiscible in water) assisted with 
disperser solvent (miscible in both water and extraction 
solvents)  within  aqueous  solution  which  lead  to  very 
high  contact  area  between  aqueous  phase  and 
extraction solvent.
22 The ease of the operation, speed, 
lower sample volume, low cost, high recovery and high 
enhancement factor are some advantages of DLLME. 
With the development of DLLME, the principles and 
the  applications  of  this  new  technique  have  been 
reviewed  recently
23,24  and  its  application  extended  to 
separation,  pre–concentration  and  determination  of 
organic
21,25–27  and  inorganic
22,28–30  compounds  in 
different  samples.  However,  to  the  best  of  our 
knowledge,  this  is  the  first  report  concerning  PX 
extraction using the DLLME method. 
In  this  work  a  DLLME  methodology  has  been 
developed and optimized for the extraction of PX from 
human  urine  and  pharmaceutical  formulation.  The 
extracted PX was analyzed by using spectrophotometry 
and this method was used due to ease and low cost of 
operation.  Potential  parameters  affecting  the  DLLME 
and analytical performance were studied and optimized 
systematically. Using the developed method PX can be 
analyzed  in  pharmaceutical  formulation  and  human 
urine  sample  in  a  simpler,  cheaper  and  more  rapid 
manner.  
 
Materials and Methods 
Apparatus 
Spectral measurements were carried out with Shimadzu 
UV–visible  Recording  Spectrophotometer  (UV–160 
model) using 1–cm path length and 1.5 mL quartz cells. 
A Hettich centrifuge (EBA 20 model/ Andreas Hettich 
GmbH & Co. KG, Föhrenstr. 12, D–78532 Tuttlingen, 
Germany)  with  15  mL  calibrated  centrifuge  tubes 
(Hirschmann,  EM  techcolor,  Germany)  was  used  to 
accelerate  the  phase  separation  process.  A  Corning 
M120 pH–meter (Halstead, Essex, England CO9 2DX) 
was used for checking the pH of solutions.  
 
Reagents 
All  solvents  containing  chloroform,  dichloromethane, 
carbon tetrachloride, acetone, acetonitrile, ethanol and 
methanol  were  obtained  from  Merck  (Darmstadt, 
Germany).  The  β–glucuronidase,  Type  HP–2  from 
Helix pomatia  (116,400  units/mL), was  from  Sigma–
Aldrich.  
A stock solution of 500 μg/mL of PX was prepared by 
dissolving appropriate amounts of pure drug (obtained 
from  Zahravi,  Tabriz,  Iran)  in  ethanol  and  was  kept 
away from the light in a refrigerator at approximately 
4°C.  Working  standard  solutions  were  obtained  by 
appropriate dilution of this stock standard solution. 
The acetic acid/acetate buffer (1 mol/L, pH 3.0) was 
prepared  from  sodium  acetate  trihydrate  (Riedel–De 
Haёn) and acetic acid (Merck). A 20% (w/v) solution 
of NaCl (Merck) was prepared. All other reagents were 
of analytical reagent grade or higher. Ultrapure water 
(Milli–Q Advantage A 10 system, Millipore) was used 
throughout the work. 
 
Procedure for DLLME 
From  the  PX  standard  solution  (10  µg/mL)  aliquot 
volumes,  in  the  range  0.2–4.8  µg/mL,  were  pipetted 
into 15–mL centrifuge tubes and mixed with 0.5 mL of 
1.0 mol/L acetate buffer at pH 3.0 and 2.0 mL of 20% 
NaCl solution. The contents were diluted to 5.0 mL and 
subjected to the DLLME. Seven hundred microlitres of 
methanol  (as  disperser  solvent)  containing  70  µL  of 
chloroform (as extraction solvent) was injected rapidly 
into  a  sample  solution  using  a  2.0–mL  syringe.  A 
cloudy  solution  was  rapidly  produced,  resulting  from 
fine droplets, and the PX was extracted into these fine 
droplets. The mixture was centrifuged at 3500 rpm for 
3  min  and  the  dispersed  fine  droplets  of  chloroform 
were  settled.  The  supernatant  aqueous  phase  was 
readily decanted with a Pasteur pipette. The remained 
organic  phase  was  diluted  to  700  µL  with  ethanol–
water (1:1 v/v) and the absorbance measured at 355 ± 3 
nm against a reagent blank. 
     
Procedure for pharmaceutical preparation 
The  contents  of  ten  capsules  (Pursina  Pharm.  Co., 
Tehran,  Iran),  each  containing  10  mg  PX,  were 
accurately weighed individually  and finely  powdered. 
Powdered sample containing 10 mg PX was weighed 
and placed into a 15–mL glass tube dissolved in 10–mL 
methanol and was vigorously shaken on a vortex mixer 
for  30  sec.  The  solution  was  then  filtered  and 
transferred into a 50–mL volumetric flask. The residue 
was washed in enough methanols and the solution was 
finally made up to the mark with water. Thus, a 200 
µg/mL solution of PX was obtained. This solution was 
diluted  quantitatively  to  yield  concentrations  in  the 
range  of  working  standard  solution  and  then  the  PX 
content was analyzed by the procedure proposed above. 
 
Procedure for urine sample 
Urine  sample  was  obtained  from  healthy  male 
volunteer  who  took  single  oral  dose  of  10  mg  PX 
capsule.  After  administration,  the  samples  were 
collected between 0–24 h and frozen at –20 °C until 
analysis.  The  frozen  urine  samples  were  thawed  at 
room temperature, centrifuged for 15 min at 4000 rpm 
and  then  the  supernatants  were  transferred  to  clean 
glass  tubes.  Enzymatic  deconjugation  was  performed 
according  to  the  literature,
14,16  with  some 
modifications. For this purpose, 2.0 mL of urine sample 
was transferred into 10–mL centrifuge tube and 300 μL 
of sodium acetate buffer (1.0 mol/L, pH 5.0) and 200 
μL  of  β–glucuronidase/aryl  sulphatase  (116400–1015 
IU/mL) were added. The tubes were mixed vigorously 
and  incubated  at  56°C  for  6  h.  Then  tubes  were 
centrifuged at 3000 rpm for 15 min and 0.5 mL aliquots 
of the supernatant solutions were subjected to the above 
mentioned procedure.  
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Results and Discussion 
A literature survey reveals that both spectrophotometric 
and spectrofluorimetric techniques have been the most 
employed  methods  for  the  determination  of  PX  in 
pharmaceutical  preparations.  By  taking  into  account 
that the extracted PX didn’t show any significant and 
sensitive  fluorescence  in  the  studied  conditions, 
spectrophotometric  detection  was  adopted  for  its 
monitoring after DLLME. 
The  spectrophotometric  methods  used  for  the 
determination  of  PX  are  generally  based  on  the 
oxidation  of  PX  with  different  agents,  such  as 
potassium  iodate,
3  ferric  salts,
6  ceric  ammonium 
sulfate
31 and indirect spectrophotometric determination 
of  the  reaction  products,  solid–phase 
spectrophotometry
4 and or chelating with ferric ion.
5 In 
this study, quantitative determination of PX in different 
real  samples  was  performed  by  direct 
spectrophotometry  in  order  to  avoid  of  slow 
derivatization reactions, specific or toxic agents, large 
sample volumes and/or excess use of organic solvents. 
Figure 1 shows the absorption spectrum of the target 
analyte  after  DLLME  which  exhibits  an  absorption 
band  peaking  at  355  ±  3  nm.  To  obtain  higher 
extraction efficiency, the effect of different factors such 
as  pH,  type  and  volume  of  dispersive  and  extraction 
solvents,  salt  addition  and  etc.  were  tested  using  the 
one variable at a time method.  
 
 
 
Figure 1. Absorption spectra of PX after DLLME: a) Standard solution of PX (2.0 μg/mL) (b) sample "a" after addition of NaCl (8% w/v), 
(c) 0.5 mL urine sample spiked with PX (2.0 μg/mL); other conditions: 0.5 mL of 1.0 mol/L acetate buffer at pH 3.0; extraction with 500 of 
methanol µL containing 50 µL of chloroform. 
 
Effect of pH 
It is well known that the pH of the sample solution was 
one  of  the  important  factors  affecting  the  states  of 
analytes (as ions or neutral forms). Figure 2 shows the 
effect  of  pH  on  the  absorption  signal  of  the  target 
analyte.  As  can  be  seen,  the  signal  intensity  of  PX 
improved with the increasing of pH from 3.0 to  3.5, 
and  then  decreased  in  pH  3.5–12.0.  This  can  be 
explained by the following reasons: Analytes in neutral 
forms  are  much  easier  to  be  extracted  by  extraction 
solvent  than  those  in  ion  forms  due  to  their  strong 
affinity. According to the literature,
8,32 the pKa values 
of PX are 1.81 and 5.12. By considering these values, 
below pH 1.8 both the pyridyl and enolic groups are 
mostly prorogated (LH
2+,  positive global charge)  and 
above  pH  5.1  these  groups  are  deprotonated  (L
–, 
negative  global  charge).  In  the  pH  range  1.8–5.1,  a 
tautomeric  equilibrium  between  the  neutral  molecule 
(LH
0) and the zwitterions (LH
±) is established.
8 Hence, 
when the pH of the solution was between 1.8–5.1, the 
analyte is neutral form in aqueous solution which has a 
greater  tendency  to  be  extracted  into  the  extraction 
solvent. Accordingly, the pH of samples was controlled 
at 3.0 by acetate buffer for subsequent study. 
 
 
Figure  2.  Effect  of  pH  on  the  analytical  responses,  PX 
(1.2  μg/mL);  other  conditions:  2.0  mL  of  20%  NaCl;  0.5 
mL  of  1.0  mol/L  acetate  buffer  at  pH  3.0;  extraction  with 
500 of methanol µL containing 50 µL of chloroform.  
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Effect of the extraction and disperser solvent type 
The type of extraction solvent used in DLLME is an 
important  factor  for  efficient  extraction.  The  solvent 
should be denser than water. Moreover it should have 
more  capability  for  the  extraction  of  interested 
compounds  and  lower  solubility  in  water.  Thus, 
chloroform, dichloromethane and carbon tetrachloride 
were studied as extraction solvent. On the other hand, 
the  selection  of  a  dispersive  solvent  is  limited  to 
solvents  such  as  methanol,  ethanol,  acetonitrile  and 
acetone,  that  are  miscible  with  both  water  and 
extraction solvents. 
In  this  study,  all  combinations  of  dichloromethane, 
chloroform  and  carbon  tetrachloride  as  extraction 
solvents  (50  µL)  and  methanol,  ethanol,  acetonitrile 
and  acetone  as  dispersive  solvents  (500  µL)  were 
tested.  The  results  shown  in  Figure  3  indicated  that, 
when dichloromethane was used as extraction solvent, 
no  cloudy  state  was  observed  and  also  no  sediment 
droplet of extract was found on the bottom of the tube 
after  centrifuging.  With  carbon  tetrachloride  and 
chloroform, a two–phase system was formed with all 
four  dispersive  solvents  but  in  the  case  of  carbon 
tetrachloride low signals was observed, probably due to 
little extractability of the analyte in this solvent. While 
in the case  of chloroform with  methanol more  stable 
two–phase systems and higher signals were observed. 
Thus  chloroform  and  methanol  was  selected  as 
extraction  and  disperser  solvents,  respectively,  in 
subsequent experiments.  
 
 
Figure  3.  Effect  of  the  type  of  extraction  and  dispersant 
solvents on the analytical responses, EtOH: ethanol, MeOH: 
methanol,  Ac:  acetone,  ACN:  Acetonitrile,  PX  (1.8  μg/mL); 
other conditions have been mentioned in Figure 2. 
 
Effect of the extraction and disperser solvent volume 
The effect of the volume of the extraction solvent on 
the  analytical  signals  was  investigated.  Experiments 
were performed with different volumes of chloroform 
(in the range of 30–90 µL) as the extraction solvent by 
fixing the volume of the methanol at 500 µL. Figure 4 
indicates  that  the  absorbance  increased  by  increasing 
the  volume  of  the  chloroform  to  70  µL  and  then 
remained approximately constant by further increasing 
of its volume between 70 and 90 µL. Thus 70 µL of 
chloroform was used in other experiments. In order to 
examine  the  effect  of  the  disperser  solvent  volume, 
solutions containing different volumes of methanol (in 
the  range  of  400–800  µL)  containing  70  µL  of 
chloroform  were  subjected  to  the  same  DLLME 
procedure.  As  shown  in  Figure  5,  the  absorbance 
reached  to  its  maximum  value  at  700  µL  of  the 
methanol.  Thus  this  volume  was  used  in  other 
experiments. 
 
 
Figure 4. Effect of the extraction solvent (CHCl3) volume on 
the analytical signals, PX (1.8 μg/mL); other conditions have 
been mentioned in Figure 2. 
 
 
Figure 5. Effect of the dispersant solvent (MeOH) volume on 
the analytical signals, PX (1.8 μg/mL); other conditions have 
been mentioned in Figure 2. 
 
Effect of salt addition 
For investigating the influence of ionic strength on the 
extraction efficiency of DLLME, various experiments 
were  performed  by  adding  different  amount  of  NaCl 
(0–15%, w/v) when other experimental conditions were 
kept  constant.  It  was  found  that  the  absorbance  was 
increased by increasing the amount of NaCl from 0 to 
8%, and then decreased gradually by further increase of 
the salt concentration  (see Figure 6).  Based on  these 
results, 8% (w/v) NaCl was chosen as the optimal salt 
concentration in the DLLME procedure. 
 
Method validation 
The  optimized  DLLME–spectrophotometric  method 
was  validated  according  to  ICH  guidelines.
33  
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Calibration graphs were obtained by DLLME of 5 mL 
of standard solutions containing known amount of the 
PX and under the experimental conditions specified in 
the  procedure.  The  remained  phase  (≈100  µL)  was 
diluted to 0.7 mL with ethanol: water (1:1 v/v) and the 
absorbance  measured.  Thus,  the  theoretical  and 
experimental  preconcentration  factors  of  50  and  ≈7 
were achieved. The calibration curve for the detection 
of PX was linear over the concentration range 0.2 to 4.8 
µg/mL
 and the corresponding regression equation was: 
Abs. = 0.1711C – 0.0154 (r = 0.9965), where Abs. is 
the absorbance intensity, C is the concentration of PX 
as µg/mL and r is correlation coefficient. 
Table  1  indicates  the  analytical  characteristics  of  the 
proposed  method.  Limit  of  detection  (LOD)  was 
calculated as 3σs/R, where σs is the standard deviation 
of the blank and R the slope of the calibration curve, 
and  found  to  be  0.058  μg/mL.  This  LOD  was 
sufficiently low to be valuable for the determination of 
PX in different biological fluids. In addition, obtained 
linear  range,  LOD  and  RSD  were  comparable  with 
those reported in other extractive methods (see Table 1). 
 
 
 
Figure 6. Effect of salt amount on the analytical signals, PX 
(1.8 μg/mL); other conditions have been mentioned in Figure 2. 
 
Table1. Analytical characteristics of the different extractive methods. 
Method 
Sample & 
Ex. method 
Concentration 
range (μg/mL) 
Slope  Intercept  r  RSD%  LOD (μg/mL) 
Mean recovery 
(%) 
Ref. 
E.C  sensor  P.P  5.2×10
-5-10
-2  55.8  22.5  -  0.83-1.4  0.795  98.8-102  1 
S  B.S  0.50-12  0.348  -0.014  0.9998  0.13-2.0  0.290
a  89.4  2 
S  P.P  0.05-1.1  1.07  -0.033  -  0.62-2.6  0.012
b  99.7-100  3 
Solid phase S  P.P  0.5-10  5.10×10
-2  0.013  0.9950  1.8  0.100  95.7-104  4 
Derivative S  P.P  2.4-20  5.20×10
-3  -4.04×10
-4  0.9986  1.29  -  99.7  5 
HPLC  –  5.0-20  1.14×10
4  2.72×10
3  0.9996  0.82  -  -  - 
S  P.P  0.20-6.5  0.112  0.021  0.9993  0.93  8.35-8.75
b  98.9-99.6  6 
    0.05-6.5  0.112  0.032  0.9989  0.88  -  98.9-99.5  - 
F  P.P  0.02-1.0  28.6  2.90  0.9990  1.6  0.020  100  8 
F  P.P  0.03-0.20  42.3  1.02  0.9930  2.9  0.010  100  9 
F 
P.P and 
B.S & LLE 
0.05-1.5  18.0  3.29  0.9993  1.3-1.6  0.015  99-104  10 
Luminescence 
P.P and 
B.S 
0.2-1.0  1.83  -0.024  0.9955  0.5-3.9  0.029  97.5-100.8  12 
S  B.S  1.0-10  -  -  0.9777-0.9975  1.0(S.D)  0.030-0.040  99-114  13 
HPLC  B.S & LLE  0.05-20  0.463  -4.70×10
-3  0.9999  0.6-2.9  0.050  88-99  16 
HPLC  B.S & LLE  7.2×10
-4-0.6  0.727-1.44  -0.197-0.574  0.9960  3.2  7.20×10
-4a  57.8-67.8  18 
HP–TLC  B.S & LLE  0.1-15  0.689  0.046  0.9970  3.1-4.9  0.050  94.8  19 
HPLC  B.S & P.P  0.1-6.0  0.972  0.011  0.9998  4.2-5.4  0.020  100  20 
S  -  0.2-4.8  0.171  -0.015  0.9965  2.8  0.058  97-110 
This 
work 
E. C=Electrochemical; S.D=standard deviation; S=Spectrophotometry; F=Spectrofluorimetry; Pharmaceutical preparation=P.P; Biological sample=B.S; 
P.P=protein precipitation; a LOQ has been reported; b sensitivity has been reported. 
 
 
The interferences 
As can be seen from Figure 1, the analytical signals in 
the presence of urine are higher than that obtained in 
the absence of it. This can be attributed to the chemical 
composition of the urine and present salts which can 
contribute at higher extraction efficiencies of PX, due 
to salting out effect. It was found that the addition of 
NaCl  to  the  standard  solutions  of  PX,  up  to 
concentrations of 8% (w/v), can increase its extraction 
efficiency  due  to  salting  out  effect,  therefore  remove 
this interference effect. 
 
The validation and application of the method 
Application to the commercial formulation 
The proposed method was successfully applied to the 
analysis of PX in its pharmaceutical dosage form (10  
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mg per capsule) and the results are shown in Table 2. 
The  data  in  this  table  show  that  the  PX  content 
measured  by  the  proposed  method  was  in  excellent 
agreement  with  those  obtained  by  an  independent 
spectrofluorimetric  method.
10  A  comparison  using  t–
test at 95% confidence interval demonstrates that there 
isn’t  any  significant  difference  among  the  achieved 
results using these two methods.
34 The accuracy of the 
proposed  method  was  further  tested  by  performing 
recovery  experiments  on  the  solutions  prepared  from 
PX formulation. The results are summarized in Table 3 
and  recoveries  ranged  from  104–110%.  These 
recoveries indicate that no significant matrix effect was 
observed in the proposed procedure. 
 
Table 2. Results of recoveries of spiked samples. 
Sample 
PX added 
(μg/mL) 
†PX found 
(μg/mL) 
Recovery (%) 
PX solution* 
(μg/mL) 
0.5  0.52 ± 0.015  104 
1.0  1.07 ± 0.031  107 
1.5  1.65 ± 0.048  110 
Human urine
♥ 
0.5  0.51 ± 0.015  102 
1.0  0.97 ± 0.029  97 
1.5  1.62 ± 0.048  108 
*Prepared from drug formulation. 
♥A 0.5 mL portion of urine sample was used for recovery experiments. 
†Average of three determinations ± standard deviation. 
 
 
Table 3. Determination of PX in pharmaceutical preparation. 
Method 
*PX 
concentration 
(μg/mL) 
†The tabulated t & F 
values 
Spectrofluorimetry [10]
  11.0 ± 0.170  t = 1.78 (2.78) 
Spectrophotometry 
(this work) 
10.5 ± 0.350  F = 4.24 (19) 
*Average of three determinations ± standard deviation. 
†Figures between parenthesis are the tabulated t and F values 
at p = 0.05.
34 
 
Application to the human urine 
Drug–free  urine  sample  obtained  from  healthy 
volunteer was used for recovery experiments. Aliquots 
of  0.5  mL  of  urine  sample  was  spiked  with  certain 
concentrations  of  PX  and  subjected  to  the  recovery 
experiments. The obtained recoveries ranged from 97 
to  108%,  as  shown  in  Table  2,  and  seem  to  be 
satisfactory. Typical spectra of a standard solution of 
PX,  blank  urine  and  a  urine  sample  taken  from  a 
volunteer after β-glucuronidase treatment are illustrated 
in Figure 7.  No additional picks  due to  interferences 
were observed at the analytical absorption wavelength. 
Thus the coincidence of absorption spectra along with 
reasonable  recoveries  indicated  that  no  significant 
matrix effect was encountered in the proposed method.  
 
 
 
 
Figure 7. Absorption spectra of (a) urine blank, (b) Standard solution of PX (1.8 μg/mL) (c) collected urine after oral administration of 10 
mg of PX and β–glucuronidase treatment; other conditions have been mentioned in Figure 2. 
 
The proposed method was successfully applied to the 
determination of PX in human urine. For this purpose, 
urine was collected for 24 h after a single oral dose of 
10 mg of PX to one volunteer. It must be mentioned 
that according to the literature,
2 there is an extensive 
overlap  of  the  spectral  bands  of  PX  and  5–HP. 
Therefore the  total  excreted  drug,  i.e.  unchanged  PX 
and its metabolites, can be determined as PX after β–
glucuronidase treatment and performing the analysis in 
the analytical absorption wavelength of PX. 
The  average  concentration  of  PX  was  found  to  be 
2.99±0.09 µg/mL in a total volume of 0.79 L of urine. 
In the present study, approximately 23.6% of the PX 
dose  was  recovered  in  urine  as  the  5'–hydroxy  
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metabolite and its glucuronide conjugate, which was in 
accordance  with  values  reported  in  the  literature.
35,36 
Also,  urinary  excretion  of  unchanged  PX  was 
negligible and below the detection limit of the assay. 
 
Conclusion 
The feasibility of employing DLLME as a simple and 
effective tool for the extraction of PX from different 
real  samples  has  been  studied.  The  method  was 
validated  using  real  samples  and  applied  to  the 
determination of PX in human urine. Compared to the 
HPLC,  the  proposed  method  allows  carrying  out  the 
analysis of PX with low operational costs, simplicity of 
instrumentation  and  without  further  sample  clean–up 
steps.  Thus,  the  time  and  cost  of  analysis  can  be 
significantly decreased in addition to other well–known 
advantages of DLLME methodology. The method can 
be  further  developed  by  combining  DLLME 
methodology  with  the  proper  HPLC  method  for  the 
separation  and  determination  of  each  PX  and  its 
metabolites. 
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